VRCA stock forecast, quote, news & analysis
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers... Show more
Why Verrica Pharmaceuticals (VRCA) Stock Is Down -24% in the Last 30 Days
Key Takeaways
- Verrica Pharmaceuticals (VRCA) declined roughly 24% over the last 30 days, falling from about $4.18 to $3.19 per share.
- The drop extends a longer slide: shares are down approximately 37% over the last quarter and trade near the low end of their 52-week range of $3.08 to $9.82.
- Persistent operating losses, a disclosed going-concern risk, and capital needs continue to weigh on sentiment even as demand for the company's YCANTH product grows.
- In Q2 2026, YCANTH dispensed applicator units rose 46% year over year, yet total revenue fell to $5.9 million amid lower one-time collaboration revenue.
- A non-dilutive credit facility of up to $27.5 million from the company's chairman is intended to extend its cash runway, but management has signaled it will still seek additional capital.
- Key catalysts ahead include Phase 3 common-warts topline data (targeted for mid-2027) and the planned Phase 3 initiation of VP-315 for basal cell carcinoma.
- For additional context on valuation and catalysts, explore the company's Price Targets, Earnings, and Forecast pages.
- To discover automated strategies across the market, explore Trending AI Robots.
Verrica Pharmaceuticals (VRCA) Company Overview and Market Position
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company based in West Chester, Pennsylvania, focused on developing and commercializing treatments for skin diseases, including skin cancers. Its lead commercial product is YCANTH (VP-102), a proprietary drug-device combination containing a controlled formulation of cantharidin delivered through a single-use applicator. YCANTH is the first and only healthcare professional-administered treatment approved by the FDA for molluscum contagiosum in adult and pediatric patients two years of age and older, a highly contagious viral skin infection affecting an estimated six million people in the United States, primarily children.
Beyond molluscum, Verrica is advancing YCANTH for the treatment of common warts, which it describes as a substantial remaining unmet need in medical dermatology. The company is also developing VP-315 (ruxotemitide), a potential first-in-class oncolytic peptide immunotherapy licensed from Lytix Biopharma, as a non-surgical option for basal cell carcinoma and other non-melanoma skin cancers. Investors follow VRCA for its commercial ramp of YCANTH, its international expansion efforts, and the readouts from its late-stage pipeline.
Verrica Pharmaceuticals (VRCA) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, VRCA has moved decisively lower. From a closing price near $4.18 in early October, the stock fell to about $3.19, a decline of roughly 24%. The move was not a single-day event; the stock shed value in several downswings, including sharp single-session declines that reflected thin trading liquidity and heightened sensitivity to company-specific and sector-wide pressures.
The last-quarter trend tells a similar story. Beginning the period near $5.08 in early August, shares declined approximately 37% to their current level. This multi-month slide has brought VRCA close to its 52-week low of $3.08, well below its 52-week high of $9.82, and reflects a sustained de-rating even as the company reports accelerating YCANTH unit demand.
What Drove VRCA Stock Price in the Last 30 Days
The recent decline has been driven less by a single catalyst than by a combination of fundamental and structural pressures. Verrica continues to report significant net losses while its cash position remains constrained, and the company has itself disclosed substantial doubt about its ability to continue as a going concern without additional funding. That disclosure, combined with the prospect of future equity or debt financing, has kept a dilution overhang on the stock.
At the same time, VRCA is a micro-cap name with limited average daily trading volume, which can amplify price swings in either direction. Small-cap biotechnology stocks have also faced broad risk-off sentiment, further pressuring names that depend on future capital raises. These factors outweighed the company's improving commercial fundamentals during the period, keeping the bias negative despite progress in YCANTH demand.
What Drove VRCA Stock Performance Over the Last Quarter
The quarterly decline reflects a longer-running tension between operational progress and financial strain. In August, Verrica reported second-quarter 2026 results showing accelerating YCANTH momentum, with dispensed applicator units up 46% year over year and 28% sequentially. However, total revenue fell to $5.9 million from $12.7 million a year earlier because the prior-year period included an $8.0 million one-time milestone, and the company posted a net loss of $13.2 million.
Positively, the company secured a non-dilutive credit facility of up to $27.5 million from an entity controlled by Chairman Paul B. Manning, announced an Israeli distribution agreement for YCANTH, and continued enrolling its global Phase 3 common-warts program. Yet investors remained focused on the path to profitability, the going-concern disclosure, and the likelihood of additional capital raises, which overshadowed the commercial and pipeline advances over the quarter.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of the platform's highest-performing and most relevant AI trading bots. Tickeron offers hundreds of AI-driven bots that collectively trade thousands of tickers, but only a focused group appears in this trending section. Each bot uses a distinct strategy, operates across different timeframes, and is evaluated on its own performance metrics, so no two bots are alike. Traders and investors can browse the curated list to compare approaches and find automated strategies that align with their goals. Exploring the Trending AI Robots page can be a useful starting point for anyone evaluating systematic, data-driven trading tools.
VRCA Stock Forecast Drivers: What Investors Should Watch Next
Investors are likely to focus on several forward-looking factors. First is the global Phase 3 program evaluating YCANTH for common warts, with topline data currently targeted for mid-2027; a positive readout could expand the product's addressable market meaningfully. Second, Verrica has signaled plans to initiate Phase 3 development of VP-315 for basal cell carcinoma, with a target in early 2027. Third, the company is expanding its U.S. sales force toward roughly 50 representatives by year-end, which could influence near-term YCANTH growth.
Financially, market participants will monitor cash runway, any additional capital raises, and the company's progress toward reducing operating losses. Regulatory and partnership milestones, including European marketing authorization efforts and international commercialization, remain important swing factors. As with any early-stage commercial biotech, results, funding decisions, and clinical data will continue to shape the stock's trajectory.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
VRCA's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for VRCA moved out of oversold territory on November 03, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 32 of the 34 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on VRCA as a result. In 74 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for VRCA just turned positive on November 03, 2026. Looking at past instances where VRCA's MACD turned positive, the stock continued to rise in 38 of 44 cases over the following month. The odds of a continued upward trend are 86%.
Following a +16.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where VRCA advanced for three days, in 221 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 46 cases where VRCA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRCA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
VRCA broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for VRCA entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. VRCA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.724) is normal, around the industry mean (3.498). P/E Ratio (-1.833) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.496) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VRCA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry Biotechnology